Physician profile
Daniel C Coffey
NPI 1710961305
$1,808.15
in general payments reported to CMS, 2019-2025
23 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2021: $59.34 · 2022: $352 · 2023: $499 · 2024: $391 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192 · Education: $36.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.61 |
| Education | $36.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $467.62 | 2021-2025 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $327.95 | 2022-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $140.51 | 2023-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.69 | 2022-2024 | Xifaxan |
| La Jolla Pharmaceutical Company | $114.39 | 2023 | Xerava |
| Abbvie INC. | $106.58 | 2024-2025 | |
| Braintree Laboratories, INC. | $100.39 | 2019-2023 | Sutab |
| Heron Therapeutics, INC. | $47.51 | 2023-2025 | Zynrelef |
| Celltrion USA INC. | $38.69 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $38.50 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $35.57 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $33.83 | 2023-2024 | Ocaliva |
| Coloplast Corp | $32.37 | 2025 | |
| Ethicon US, LLC | $31.29 | 2024 | Proximate |
| Covidien LP | $30.41 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $23.47 | 2019 | |
| Thd America, INC. | $20.21 | 2024 | |
| Lilly USA, LLC | $17.84 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $17.76 | 2025 | Iqirvo |
| Qol Medical, LLC | $17.00 | 2019 | |
| Cook Medical LLC | $16.23 | 2019 | |
| Shire North American Group INC | $15.26 | 2019 | |
| Reprise Biomedical, INC. | $14.08 | 2023 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.